Food and Drug AdministrationImportant note: Information in this article was accurate in 2007. The state of the art may have changed since the publication date.
Click here to return to FDA main menu
DonateNow
Print this Article


Final Guidance: The Role of HIV Resistance Testing in Antiretroviral Drug Development.

Food and Drug Administration - November 5, 2007
Richard Klein & Kimberly Struble

The Food and Drug Administration is publishing final Guidance for Industry on the Role of HIV Resistance Testing in Antiretroviral Drug Development. This final guidance discusses the nonclinical studies (mechanism of action; antiviral activity in vitro; cytotoxicity/therapeutic index; and the effects of serum protein binding on antiviral activity) the agency recommends be completed prior to the initiation of phase 1 clinical studies in HIV-infected patients. In addition, the guidance addresses the use of resistance testing in the clinical phases of drug development and recommends the type of information that should be collected and the types of analyses that should be conducted to characterize an antiretroviral's resistance profile.

The guidance also discusses the role of resistance testing in initial activity and dose-finding, for study enrollment criteria, for background regimen selection, and to establish an indication.

The guidance represents the agency's current thinking on the role of HIV resistance testing in antiretroviral drug development. As with all FDA guidance for industry, it does not create or confer any rights for or on any person and does not operate to bind FDA or the public. An alternative approach may be used if such approach satisfies the requirements of the applicable statutes and regulations.

A copy of the final guidance document is attached. You may find this and other Guidance for Industry on the FDA web site at http://www.fda.gov/cder/guidance/index.htm

Richard Klein
Office of Special Health Issues
Food and Drug Administration

Kimberly Struble
Division of Antiviral Drug Products
Food and Drug Administration


071105
FD071103

SOURCE: Food and Drug Administration (FDA).

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 2007. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2007. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .